Interestingly, as cancer cells could recover from senescence and senescent cells secrete soluble factors that promote tumor growth [117], the use of drugs that selectively kill senescent cells (known as senolytics), such as the BCL-xL inhibitor navitoclax, in combination with senescence inducers and chloroquine should be a highly effective anticancer strategy against both LKB1-proficient and defective cancers. Here, BCL2L1 is linked to cancer.